[Clinical study of a preparation with bronchomucotropic activity: guacetisal].
An open clinical study has been carried out on 40 patients of both sexes suffering from prevalently chronic bronchopneumopathy, with a suspension of guacetisal for adults. The drug is a new bronchomucotropic synthesized by the Bayer Italia S.p.A. Research Laboratories. The improvement in the clinical picture was very evident in 55% of cases and is in favour of an overall positive opinion of the drug's activity bearing in mind that the pathology considered would not in any case have permitted the achievement of complete resolution. The drug was very well tolerated and presented marked mucopoietic and anti-inflammatory properties at a dose of 1 spoonful (10 ml) 2-3 times a day.
D000368:Aged; D001241:Aspirin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003371:Cough / Q000188:drug therapy; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D011656:Pulmonary Emphysema / Q000188:drug therapy
D001241:Aspirin; C023557:guacetisal
Studio clinico di un preparato ad attività broncomucotropica: il guacetisal.